3ʹ,4ʹ,5ʹ,5,7-Pentamethoxyflavone sensitizes cisplatin-resistant A549 cells to cisplatin by inhibition of Nrf2 pathway

Molecules and Cells

Volumn 38, Issue 5, 2015, Pages 396-401

  Hou, Xiangyu ^a   Bai, Xupeng ^a   Gou, Xiaoli ^a   Zeng, Hang ^a   Xia, Chen ^a   Zhuang, Wei ^a   Chen, Xinmeng ^a   Zhao, Zhongxiang ^b   Huang, Min ^a   Jin, Jing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

3 ,4 ,5 ,5,7 Pentamethoxyflavone; Chemoresistance; Cisplatin; Lung cancer; Nrf2

Indexed keywords

3',4',5',5,7 PENTAMETHOXYFLAVONE; CISPLATIN; FLAVONE DERIVATIVE; GLUTAMATE CYSTEINE LIGASE; HEME OXYGENASE 1; NADPH DEHYDROGENASE QUININE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; 5,7,3',4',5'-PENTAMETHOXYFLAVONE; ANTINEOPLASTIC AGENT; FLAVONOID; NFE2L2 PROTEIN, HUMAN;

A549 CELL LINE; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; RECEPTOR DOWN REGULATION; RUTACEAE; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NF-E2-RELATED FACTOR 2; SIGNAL TRANSDUCTION;

EID: 84946403169     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.14348/molcells.2015.2183     Document Type: Article

References (37)

1. Boesch-Saadatmandi, C., Wagner, A.E., Graeser, A.C., Hundhausen, C., Wolffram, S., and Rimbach, G. (2009). Ochratoxin A impairs Nrf2-dependent gene expression in porcine kidney tubulus cells. J. Anim. Physiol. Anim. Nutr. 93, 547-554.
2. Cai, H., Sale, S., Schmid, R., Britton, R.G., Brown, K., Steward, W.P., and Gescher, A.J. (2009). Flavones as colorectal cancer chemopreventive agents--phenol-o-methylation enhances efficacy. Cancer Prev. Res. 2, 743-750.
3. Chen, F., Liu, Y., Wang, S., Guo, X., Shi, P., Wang, W., and Xu, B. (2013). Triptolide, a Chinese herbal extract, enhances drug sensitivity of resistant myeloid leukemia cell lines through downregulation of HIF-1a and Nrf2. Pharmacogenomics 14, 1305-1317.
4. Chian, S., Li, Y. Y., Wang, X.J., and Tang, X.W. (2014). Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugsvia inhibition of the Nrf2 pathway. Asian Pac. J. Cancer Prev. 15, 2911-2916.
5. D'Addario, G., Felip, E., and ESMO Guidelines Working Group. (2009). Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20, 68-70.
6. El-Sheikh, A.A., Greupink, R., Wortelboer, H.M., van den Heuvel, J.J., Schreurs, M., Koenderink, J.B., Masereeuw, R., and Russel, F.G. (2013). Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4. Transl. Res. 162, 398-409.
7. Fujimori, S., Abe, Y., Nishi, M., Hamamoto, A., Inoue, Y., Ohnishi, Y., Nishime, C., Matsumoto, H., Yamazaki, H., Kijima, H., et al. (2004). The subunits of glutamate cysteine ligase enhance cisplatin resistance in human non-small cell lung cancer xenografts in vivo. Int. J. Oncol. 25, 413-418.
8. Gao, A.M., Ke, Z.P., Shi, F., Sun, G.C., and Chen, H. (2013a). Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway. Chem. Biol. Interact. 206, 100-108.
9. Gao, A.M., Ke, Z.P., Wang, J.N., Yang, J.Y., Chen, S.Y., and Chen, H. (2013b). Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis 34, 1806-1814.
10. Hayashi, A., Suzuki, H., Itoh, K., Yamamoto, M., and Sugiyama, Y. (2003). Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein1 in mouse embryo fibroblasts. Biochem. Biophs. Res. Commun. 310, 824-829.
11. Hayes, J.D., and McMahon, M. (2009). NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem. Sci. 34, 176-188.
12. Itoh, K., Mimura, J. and Yamamoto, M. (2010). Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid. Redox Signal. 13, 1665-1678.
13. Jaiswal, A.K. (2004). Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic. Biol. Med. 36, 1199-1207.
14. Ji, X., Wang, H., Zhu, J., Zhu, L., Pan, H., Li, W., Zhou, Y., Cong, Z., Yan, F., and Chen, S. (2013). Knockdown of Nrf2 suppresses glioblastoma angiogenesis by inhibiting hypoxia-induced activation of HIF-1alpha. Int. J. Cancer 135, 574-584.
15. Kim, J.K., and Jang, H.D. (2014). Nrf2-mediated HO-1 induction coupled with the ERK signaling pathway contributes to indirect antioxidant capacity of caffeic acid phenethyl ester in HepG2 cells. Int. J. Mol. Sci. 15, 12149-12165.
16. Kinoshita, T. and Firman, K. (1997). Myricetin 5,7,3K,4,5,-pentamethyl ether and other methylated flavonoids from Murraya Paniculata. Phytochemistry 45, 179-181
17. Kiyohara, C., Yoshimasu, K., Takayama, K., and Nakanishi, Y. (2005). NQO1, MPO, and the risk of lung cancer: A HuGE review. Genet. Med. 7, 463-478.
18. Kweon, M.H., Adhami, V.M., Lee, J.S., and Mukhtar, H. (2006). Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J. Biol. Chem. 281, 33761-33772.
19. Langer, C.J., Manola, J., Bernardo, P., Kugler, J.W., Bonomi, P., Cella, D., and Johnson, D.H. (2002). Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of eastern cooperative oncology group 5592, a randomized trial. J. Natl. Cancer Inst. 94, 173-181.
20. Lim, J., Lee, S.H., Cho, S., Lee, I.S., Kang, B.Y., and Choi, H.J. (2013). 4-methoxychalcone enhances cisplatin-induced oxidative stress and cytotoxicity by inhibiting the Nrf2/ARE-mediated defense mechanism in A549 lung cancer cells. Mol. Cells 36, 340-346.
21. Longley, D.B., and Johnston, P.G. (2005). Molecular mechanisms of drug resistance. J. Pathol. 205, 275-292.
22. Lu, Y.Q., Wang, L.Y., Luo, Y.P. (2011). The antifungal activities and composition analysis of the essential oil from Murraya paniculata. Agrochemicals 50, 443-446.
23. Maher, J.M., Aleksunes, L.M., Dieter, M.Z., Tanaka, Y., Peters, J.M., Manautou, J.E., and Klaassen, C.D. (2008). Nrf2-and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol. Sci. 106, 319-328.
24. Na, H.K., and Surh, Y.J. (2014). Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. Free Radic. Biol. Med. 67, 353-365.
25. Ohnuma, T., Matsumoto, T., Itoi, A., Ayako Kawana, Nishiyama, T., Ogura, K., and Hiratsuka, A. (2011). Enhanced sensitivity of A549 cells to the cytotoxic action of anticancer drugs via suppression of Nrf2 by procyanidins from Cinnamomi Cortex extract. Biochem. Biophys. Res. Commun. 413, 3623-3629.
26. Ren, D., Villeneuve, N.F., Jiang, T., Wu, T., Lau, A., Toppin, H.A., and Zhang, D.D. (2011). Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc. Natl. Acad. Sci. USA 108, 1433-1438.
27. Shim, G.S., Manandhar, S., Shin, D.H., Kim, T.H., and Kwak, M.K. (2009). Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radic. Biol. Med. 47, 1619-1631.
28. Signore, M., Ricci-Vitiani, L., and De Maria, R. (2013). Targeting apoptosis pathways in cancer stem cells. Cancer Lett. 332, 374-382.
29. Singh, A., Misra V., Thimmulappa R.K., Lee H., Ames S., Hoque M.O., Herman J.G., Baylin S.B., Sidransky D., Gabrielson E., et al. (2006) Dysfunctional KEAP1-NRF2 interaction in non-smallcell lung cancer. PLoS Med. 3, 1865-1874.
30. Singh, A., Boldin-Adamsky, S., Thimmulappa, R.K., Rath, S.K., Ashush, H., Coulter, J., Blackford, A., Goodman, S.N., Bunz, F., Watson, W.H., et al. (2008). RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 68, 7975-7984.
31. Soeiro, M.N., and Castro, S.L. (2009). Trypanosoma cruzi targets for new chemotherapeutic approaches. Expert Opin. Ther. Targets 13, 105-121.
32. Tang, X., Wang, H., Fan, L., Wu, X., Xin, A., Ren, H., and Wang, X.J. (2011). Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic. Biol. Med. 50, 1599-1609.
33. Tomazela, D.M., Pupo, M.T., Passador, E.A., da Silva, M.F., Vieira, P.C., Fernandes, J.B., Fo, E.R., Oliva, G., and Pirani, J.R. (2000). Pyrano chalcones and a flavone from Neoraputia magnifica and their Trypanosoma cruzi glycosomal glyceraldehyde 3-phosphate dehydrogenase inhibitory activities. Phytochemistry 55, 643-651.
34. Venugopal, R., and Jaiswal, A.K. (1996). Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc. Natl. Acad. Sci. USA 93, 14960-14965.
35. Wang, X.J., Sun, Z., Villeneuve, N.F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G.T., et al. (2008). Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29, 1235-1243.
36. Was, H., Cichon, T., Smolarczyk, R., Rudnicka, D., Stopa, M., Chevalier, C., Leger, J.J., Lackowska, B., Grochot, A., Bojkowska, K., et al. (2006). Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice. Am. J. Pathol. 169, 2181-2198.
37. Zhong, Y., Zhang, F., Sun, Z., Zhou, W., Li, Z.Y., You, Q.D., Guo, Q.L., and Hu, R. (2013). Drug resistance associates with activation of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response. Mol. Carcinog. 52, 824-834.